Over the next 5 years my career goals include (1) conducting original research on the epidemiology and impact of metabolic complications of HIV disease, (2) developing a comprehensive program to mentor trainees with career interests in patient-oriented research, (3) the expansion of my research program to include an international component. The rich diversity of ongoing basic and clinical research on HIV infection at UCLA and the facilities available in the Center for Clinical AIDS Research and Education provide tremendous resources to enhance my experience as a clinical investigator and provide a stimulating atmosphere for my trainees. The K24 Award will help me to achieve my career goals by providing me with a significant amount of protected time to devote to mentoring my trainees, gaining additional training for myself in biostatistics and focusing on my own research program. This application describes a comprehensive training program for fellows, which includes formal training in biostatistics and clinical research methods. In addition four research projects are described. The proposed research will investigate the natural history of insulin resistance among a cohort of well-characterized patients on long term HAART and examine in detail gender differences in prevalence of insulin resistance and lipid abnormalities in men and women enrolled in a cross-sectional study of metabolic complications. A prospective, matched, cohort study will compare measurements of carotid intima medial thickness between patients with HIV infection treated with a protease inhibitor or no therapy to patients without HIV infection in order to test the hypothesis that protease inhibitor therapy is associated with an increased risk of subclinical atherosclerosis. A randomized clinical trial comparing three antiretroviral regimens among subjects enrolled at twelve sites located in resource poor settings around the world will provide the opportunity to examine the factors associated with the development of immune reconstitution syndromes and to determine whether these syndromes predict an altered response to HAART. The strong support from my Division Chief and Department Chair to allow me to reduce my clinical and administrative responsibilities will greatly facilitate my success in achieving my goals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24AI056933-02
Application #
6781713
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Program Officer
Roe, Joanad'Arc C
Project Start
2003-08-01
Project End
2008-04-30
Budget Start
2004-05-01
Budget End
2005-04-30
Support Year
2
Fiscal Year
2004
Total Cost
$145,597
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Kelesidis, Theodoros; Tran, Thuy Tien T; Brown, Todd T et al. (2017) Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antivir Ther 22:113-126
Bhagwat, Priya; Ofotokun, Ighovwerha; McComsey, Grace A et al. (2017) Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes. Antivir Ther 22:577-586
Erlandson, Kristine M; Fiorillo, Suzanne; Masawi, Fadzai et al. (2017) Antiretroviral initiation is associated with increased skeletal muscle area and fat content. AIDS 31:1831-1838
Kelesidis, Theodoros; Jackson, Nicholas; McComsey, Grace A et al. (2016) Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS 30:2625-2633
McComsey, Grace A; Moser, Carlee; Currier, Judith et al. (2016) Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis 62:853-62
Kelesidis, Theodoros; Moser, Carlee; Stein, James H et al. (2016) Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. J Infect Dis 214:748-52
Hoffman, Risa M; Lake, Jordan E; Wilhalme, Holly M et al. (2016) Vitamin D Levels and Markers of Inflammation and Metabolism in HIV-Infected Individuals on Suppressive Antiretroviral Therapy. AIDS Res Hum Retroviruses 32:247-54
Dirajlal-Fargo, Sahera; Moser, Carlee; Brown, Todd T et al. (2016) Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. Open Forum Infect Dis 3:ofw174
Hoffman, Risa M; Jaycocks, Amber; Vardavas, Raffaele et al. (2015) Benefits of PrEP as an Adjunctive Method of HIV Prevention During Attempted Conception Between HIV-uninfected Women and HIV-infected Male Partners. J Infect Dis 212:1534-43
Thio, Chloe L; Smeaton, Laura; Hollabaugh, Kimberly et al. (2015) Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS 29:1173-82

Showing the most recent 10 out of 66 publications